Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000796704 | SCV000936228 | uncertain significance | Myofibrillar myopathy 5; Distal myopathy with posterior leg and anterior hand involvement; Hypertrophic cardiomyopathy 26; Dilated Cardiomyopathy, Dominant | 2022-11-24 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on FLNC protein function. ClinVar contains an entry for this variant (Variation ID: 643083). This variant has not been reported in the literature in individuals affected with FLNC-related conditions. This variant is present in population databases (rs751963297, gnomAD 0.006%). This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 1201 of the FLNC protein (p.Glu1201Lys). |
Revvity Omics, |
RCV003144603 | SCV003833201 | uncertain significance | not provided | 2021-08-28 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004027572 | SCV005017732 | uncertain significance | Cardiovascular phenotype | 2023-11-23 | criteria provided, single submitter | clinical testing | The p.E1201K variant (also known as c.3601G>A), located in coding exon 21 of the FLNC gene, results from a G to A substitution at nucleotide position 3601. The glutamic acid at codon 1201 is replaced by lysine, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |